Fatty liver reexamined choline and mitochondrial toxin amelioration.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic, animal, and preliminary human literature without systematic review methodology
PubMed 41378252 · doi:10.4331/wjbc.v16.i4.111831
What was done
This narrative review synthesized mechanistic, animal, and early clinical literature evaluating the role of choline deficiency and mitochondrial stressors (specifically ethanol and excess linoleic acid) in fatty liver pathogenesis, as well as the therapeutic potential of optimized choline delivery formulations (such as citicoline).
What was found
The abstract reports no numerical values or statistical metrics. Qualitatively, it notes that low choline intake correlates with increased liver fat and aminotransferases. In rodents, choline deficiency combined with ethanol or linoleic acid reduced mitochondrial membrane potential, constrained beta-oxidation, and promoted hepatic steatosis and inflammation. Preliminary small human studies indicated that choline repletion, combined with reductions in ethanol or linoleic acid, can decrease intrahepatic triglyceride levels and improve insulin sensitivity while potentially limiting trimethylamine-N-oxide formation.
Why it matters
It conceptualizes fatty liver disease as a nutritionally modifiable mitochondrial toxicosis, proposing a combined intervention strategy of toxicant reduction and high-bioavailability choline supplementation for future clinical evaluation.
Limits
The review is non-systematic and does not report quantitative effect sizes or study sample sizes in the abstract. Much of the presented mechanistic basis relies on rodent data, and human evidence is restricted to small, early-stage studies with a stated absence of large randomized controlled trials.
Cited by
- context Fatty liver can be dramatically reduced within a couple of weeks through a low-carbohydrate diet, intermittent fasting, and choline supplementation.